Portola Pharmaceuticals (NASDAQ:PTLA) posted its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($1.41) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.46) by $0.05, Briefing.com reports. Portola Pharmaceuticals had a negative net margin of 938.19% and a negative return on equity of 110.46%. The firm had revenue of $9.80 million for the quarter, compared to analyst estimates of $3.71 million. During the same period in the prior year, the firm posted ($0.95) earnings per share. The company’s quarterly revenue was down 28.4% compared to the same quarter last year.
Portola Pharmaceuticals (PTLA) traded down $10.32 during trading hours on Thursday, reaching $32.00. 6,524,429 shares of the company were exchanged, compared to its average volume of 1,049,329. The company has a market capitalization of $2,944.15, a price-to-earnings ratio of -7.41 and a beta of 1.18. The company has a current ratio of 8.31, a quick ratio of 8.31 and a debt-to-equity ratio of 0.24. Portola Pharmaceuticals has a 1-year low of $30.10 and a 1-year high of $67.10.
In other Portola Pharmaceuticals news, Director Henry Ward Wolff sold 12,000 shares of the stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $47.00, for a total transaction of $564,000.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 5.50% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was posted by Ticker Report and is the property of of Ticker Report. If you are accessing this news story on another website, it was stolen and republished in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.tickerreport.com/banking-finance/3231528/portola-pharmaceuticals-ptla-issues-quarterly-earnings-results.html.
About Portola Pharmaceuticals
Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.
Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.